Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review. - Wikidata - awgldk - TriplyDB

Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.

Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.

http://www.wikidata.org/entity/Q35167535

about

Oral antineoplastic agents: how do we care about adherence?Cost and effectiveness of video-assisted thoracoscopic surgery for clinical stage I non-small cell lung cancer: a population-based analysis Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.Cost and effectiveness of image-guided radiotherapy for non-operated localized lung cancer: a population-based propensity score-matched analysis Cost-effectiveness of neoadjuvant concurrent chemoradiotherapy versus esophagectomy for locally advanced esophageal squamous cell carcinoma: A population-based matched case-control study.Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications.Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents, an update (2013-2015).Adherence to Oral Anticancer Medications: Evolving Interprofessional Roles and Pharmacist Workforce Considerations.The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna.

P2860

Q28082909-55636545-C277-4A06-9349-83FA29772089 Q34814512-F44FA1C7-78FF-4BB5-A526-5D4D23702457 Q35662929-A6304EBB-5043-4924-8B7D-B044049B6ED1 Q36138377-7A82E972-3D55-43BE-802C-CF60FCBECADF Q36840375-44DFB30C-8EC6-4B75-9CD8-DC779116DFBF Q38810189-4620090B-C6A7-4B89-8031-C1E7180F22FB Q38835979-9B78E5D2-2A56-429D-A7D7-EFACD6E2B181 Q54940867-2517A5DE-A8F9-4B31-A298-F9D52ACF0965 Q55017077-1B1F683D-C823-4A11-968F-92E13B4C1076

P2860

Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.

http://www.wikidata.org/entity/Q35167535

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.

@ast

Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.

@en

type

label

Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.

@ast

Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.

@en

prefLabel

Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.

@ast

Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.

@en

P1433

Q35167535-A856EF87-4ABF-45EA-B09D-DCDF1133DEA4

P1476

Q35167535-8958D8A1-72CD-4C69-BD09-8226B1410BF1

P2093

Q35167535-0EA0FC6D-9335-44B5-81EA-CDABD7D63E8D

Q35167535-1A556254-578B-42CF-8453-36BF0EFCA720

Q35167535-C9D7546A-DF0A-4AD7-BAD5-6B93C3E49007

Q35167535-DB81AFF8-ABBB-481F-BD4B-27C04D17AE44

P2860

Q35167535-030EBFBD-F373-46A5-9D76-99394A48285B

Q35167535-0370EF14-5201-4D37-99BF-4E9B2F3FDC16

Q35167535-0738376C-7654-448B-BDBC-50E8A29AEC2E

Q35167535-0BE7A110-5CF1-425D-B161-9A3BE3EA6809

Q35167535-13D22459-1264-4FA9-B069-6E72EC384A5C

Q35167535-1433CE63-1CEA-4BAE-B7E4-E4AFB9798BAF

Q35167535-1766F176-03A9-4820-B955-D2651F246FB7

Q35167535-1C124358-0428-4359-9FCE-C9BFC5DBB319

Q35167535-1E85F329-4D24-4AA3-ADB0-3B7C14D6AB6C

Q35167535-26B844CC-B8C3-4763-A055-E2C1689EA582

P2888

Q35167535-1C8BC3F5-7CC0-4FCE-81A5-61C4AA8149E9

P304

Q35167535-6B1A7AC0-6927-4F56-898A-80AF6F075576

P31

Q35167535-020ED6D1-4E63-45B1-89A7-A8CF3E08EF47

P356

Q35167535-92FA9A1D-7F98-41B7-B5EE-2205F523BD2B

P433

Q35167535-3110511F-B2E0-4713-881B-A93A63B2FC4F

P478

Q35167535-BE601C57-9687-45B9-9AEF-D5443A70E029

P50

Q35167535-34B4FE02-B46A-4354-81EA-5F97937A6A98

P577

Q35167535-A672300F-B3BD-40E9-B6F2-044BECF5C55B

P698

Q35167535-DB61CAEE-2293-48B9-B1FA-346FBE6C783B

P356

S40273-014-0160-Z

P1433

PharmacoEconomics

P1476

Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.

@en

P2093

Chan Shen

http://www.w3.org/2001/XMLSchema#string

Chun-Ru Chien

http://www.w3.org/2001/XMLSchema#string

Daniel M Geynisman

http://www.w3.org/2001/XMLSchema#string

Ya-Chen Tina Shih

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer

Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.

Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

P2888

s40273-014-0160-z

P304

651-680

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40273-014-0160-Z

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Fabrice Smieliauskas

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24821281

http://www.w3.org/2001/XMLSchema#string